IP Considerations for Gene Editing in the Cell Therapy space

Published on June 10, 2024
IP Considerations for Gene Editing in the Cell Therapy space

In this article, Cellistic's Head of IP, Sergei Kurkin, addresses the critical intellectual property (IP) considerations in the rapidly evolving field of gene editing for cell therapies, including induced pluripotent stem cell (iPSC) derived therapies. The two main elements of IP strategy highlighted are:

  1. Freedom to Operate (FTO): Ensuring that the use of a technology does not infringe on existing patents.

  2. Protecting Innovation: Securing patents for new technologies to safeguard them from being copied.

 

Continue reading on website
Other news

Abzena recognized as Best Novel Treatment Development Partner 2024 by GHP

June 7, 2024
Abzena was honored to be recognized as the Best Novel Treatment Development Partner 2024 in California by the 2024 Global Excellence Awards.Biopharmaceutical CDMO Pioneer Offers De-Risked Path to Clinic and Beyond Abzena is the leading complex biologics and bioconjugate CRO and CDMO within the pharmaceutical manufacturing industry. The company supports customers from the initial discovery phase al

InnovAge Holding Corp. Announces $5.0 Million Share Repurchase Program

June 10, 2024
DENVER, June 10, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (NASDAQ: INNV) (the “Company” or “InnovAge”) announced today that its Board of Directors has approved a share repurchase program (the “Program”) that authorizes the Company to repurchase up to $5.0 million of its common stock.